Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer
A Randomized Phase III Study Evaluating Modified FOLFIRINOX (mFFX) With or Without Stereotactic Body Radiotherapy (SBRT) in the Treatment of Locally Advanced Pancreatic Cancer: A Pancreatic Cancer Radiotherapy Study Group (PanCRS) Trial
Sponsor: Stanford University
Listed as NCT01926197, this PHASE3 trial focuses on Pancreatic Cancer and remains completed. Sponsored by Stanford University, it has been updated 12 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
-
Feb 2021 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
▶ Show 7 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Nov 2019 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Mar 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Sep 2017 [monthly]
Recruiting PHASE3
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Stanford University
For direct contact, visit the study record on ClinicalTrials.gov .